'It is difficult to rely solely on a certain technology for early screening of digestive tract tumors, and it is necessary to play a 'combination punch'. You can use a technology to achieve 'preliminary screening' at home to see if you belong to a high-risk group, and then go to a medical institution for precision testing. Screening to confirm whether it is an early stage cancer, and then further diagnosis and treatment by doctors. Combining different technologies can achieve better screening results.” Wang Guiqi, member of the National Committee of the Chinese People’s Political Consultative Conference and director of the Endoscopy Department of the Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out.
Wang Guiqi (second from right), Yang Aiming (second from left), Zhang Lianglu (first from left)
Be a guest Min Daily Health Client 2022 'Two Sessions Health Policy'”
On March 12, Wang Guiqi, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Endoscopy Department of the Cancer Hospital of the Chinese Academy of Medical Sciences, Yang Aiming, a member of the National Committee of the Chinese People's Political Consultative Conference and the director of the Department of Gastroenterology of Peking Union Medical College Hospital, and Zhang Lianglu, chairman and CEO of Wuhan Emison Life Technology Co., Ltd., were guests. Min Daily Health Client 2022 'Health Policy of the Two Sessions' special session on gastrointestinal cancer to discuss the topic of gastrointestinal cancer prevention and control.
'Healthy China 2030 goals point out that it is necessary to improve the early diagnosis rate and 5-year survival rate of cancer in key areas. In terms of digestive tract tumors, China accounts for about 1/3 of the world's incidence and deaths. The region is especially high incidence.' In response to this situation, Wang Guiqi pointed out that he hoped to further improve the prevention and treatment of cancer in rural areas.
According to Wang Guiqi, 40% of the important factors that cause rural people to return to poverty are health, and 20% are accidental disabilities. It can be said that 60% are related to medical care and health. A series of health and health policies should be adopted to ensure the well-being of the people at the grassroots level. healthy. Therefore, he suggested at this year's National Two Sessions that on the basis of the current rural cancer screening and early diagnosis program, by 2030, tumor screening should further cover 750 million rural people in 2,860 counties across the country.
Yang Aiming, member of the National Committee of the Chinese People's Political Consultative Conference and director of the Department of Gastroenterology of Peking Union Medical College Hospital, has been committed to the promotion of early cancer screening. He believes that improving early diagnosis and treatment of cancer requires the attention of doctors first. If doctors pay more attention to tumor screening, the early diagnosis rate of patients will be significantly improved. The second is the need for the approval of the people. In the past, ordinary people felt that doing gastroenteroscopy was very painful and unnecessary. Through the promotion of popular science work, many ordinary people have attached great importance to this area, and many people will take the initiative to come to the hospital to ask, 'Should I have a gastroenteroscopy at my age?'
Although gastroenteroscopy is a powerful tool for early screening of gastrointestinal tumors, it is unrealistic for everyone to do this examination, and early screening requires the blessing of some new technologies.
'Before doing endoscopy, it is necessary to find an effective primary screening technique with good patient compliance, so that ordinary people can determine whether they are a high-risk group of esophageal cancer or gastric cancer at the grassroots level or in the community. If it is a high-risk group, go to Fine inspection and further diagnosis and treatment of gastrointestinal endoscopy can improve the efficiency of screening.' Wang Guiqi pointed out.
Yang Aiming said that in the near future, it may be possible to find out which patients are high-risk groups through blood tests or stool tests, so that the scope of screening can be further narrowed. Really achieve wide coverage and early screening.
Zhang Lianglu, chairman and CEO of Wuhan Amisen Life Technology Co., Ltd., pointed out that in the face of the growing demand for early screening and diagnosis of cancer, and the relative shortage of medical resources, the industry needs to provide more convenient, non-invasive and more accurate solutions. Detection method.
In recent years, there have been many advances in early tumor screening and diagnosis based on molecular detection. For example, in terms of tumor markers, DNA methylation, gene mutation, metabolomics and multi-omics technologies are developing rapidly. More and more evidence shows that DNA methylation is the most suitable type of tumor marker for early cancer screening and diagnosis, especially for digestive system tumors. The State Food and Drug Administration has also approved a number of products for early screening and early diagnosis of tumors based on gene methylation, among which there are relatively many products for colorectal cancer, and these products have gradually entered the clinic.
In the past few years, Emerson has developed products around early cancer screening and early diagnosis. Zhang Lianglu introduced that for the detection of fecal DNA in colorectal cancer, a clinical study led by Peking Union Medical College Hospital, combined detection of two gene detection targets, the detection sensitivity of colon cancer can reach more than 95% , the detection rate of precancerous lesions can reach more than 63%, and it is hoped that related products can serve clinical services as soon as possible.
Copy the link below to view the replay live
https://m.peopledailyhealth.com/trailerDetial?contentId=1dff7b55652d4bb68ddc495ef001249a
About Aichangkang, the colorectal cancer tumor detection product of Emerson
More product details
Please call 17378090801 for consultation
With outstanding product performance, Amisen Life Technology has won 4 rounds of financing of hundreds of millions of yuan and strong support from governments at all levels, and won various honorary titles.
Behind the excellent clinical performance and technology platform is the unswerving benevolence of doctors, and escorting the life and health of the public is the persistent pursuit of Emerson Life Technology!
Early tumor screening to defeat cancer
Emerson Life Technology, keep moving forward!
About Emerson Life Technology
Emerson Life Technology focuses on the early detection of high-incidence malignant tumors, providing digestive system tumors (intestinal cancer, gastric cancer, liver cancer, esophageal cancer, pancreatic cancer), gynecological tumors (cervical cancer, endometrial cancer), urinary system tumors (bladder cancer) , Pan-cancer species and other high-incidence malignant tumor genetic testing services.
The company has been based on local development for many years, and its core technology is independent and controllable. After several years of accumulation, a diversified product detection system with methylation navigation technology as the core has been established; after tens of thousands of clinical sample verifications, the screening sensitivity and specificity have reached the industry-leading level! The company has applied for 55 patents and published more than 10 cutting-edge research results. It has become one of the few multi-type cancer screening service providers in the world and an early tumor detection company that licenses external technology license-out.
